FDA issued emergency authorization of Hydroxychloroquine treatment for COVID-19 patients in the USA.
A global survey found that anti-malarial drug hydroxychloroquine was the most highly-rated treatment against the coronavirus disease 2019 (COVID-19).
This new survey completed by Sermo on March 27, 2020, reported 6,227 physicians in 30 countries found that 37 percent of those treating COVID-19 patients rated hydroxychloroquine as the “most effective therapy” from a list of 15 options.
Also, the survey of 6,227 doctors found that the most commonly prescribed treatments are 56% analgesics, 41% Azithromycin, and 33% Hydroxychloroquine.
Previously, a survey distributed on March 30, 2020, about 83 percent of independent pharmacists in the USA said ‘they should be able to dispense a limited supply of malaria drugs, as long the patient has tested positive ….. and is under a doctor’s care.’
And, on March 23rd, the U.S. Food and Drug Administration (FDA) issued emergency use authorization of Hydroxychloroquine for treatment of coronavirus patients.
Previously available for “off-label” use, the FDA now gives hospitals and doctors emergency permission to use the anti-malarial drugs hydroxychloroquine and chloroquine to treat coronavirus patients.